Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ABP 692

Other · developed by Amgen

Phase 3 Most advanced trial
AMGN Developer
1 Registered trials

What is ABP 692?

ABP 692 is an investigational drug studied in Relapsing-remitting Multiple Sclerosis (RRMS).

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Amgen (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06700343 Phase 3 Relapsing-remitting Multiple Sclerosis (RRMS) Active not recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsing-remitting Multiple Sclerosis (RRMS)

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Follow AMGN, the company behind ABP 692

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.